Christine O'Grallis
Head of Clinical Development and Medical Affairs
Replay available
Apogee Therapeutics, Inc. (APGE) Q1 2026 Earnings Call
Apogee Therapeutics, Inc. (NASDAQ: APGE) Q1 2026 earnings conference call, held 2026-03-23. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Noel Kurdi
Vice President of Investment Relations
Julian Harrison
Analyst, BTIG
Michael Yee
Analyst, UBS
Nishant Bhan
Analyst
Tyler Van Buren
Analyst, TD Cowen
David Nierengatten
Analyst, Wedbush Securities
Dr. Ruthann Vlagos
Director of Atopic Dermatitis Program, Brigham and Women's Hospital; Professor of Dermatology, Harvard Medical School
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Apogee Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.512 Welcome to the Apogee Therapeutics Conference call. 00:00:03.512 -- 00:00:07.853 At this time, all participants are in listen-only mode. 00:00:07.853 -- 00:00:12.134 There will be question and answer session after the prepared remarks. 00:00:12.134 -- 00:00:17.455 Please be advised that this call is being recorded at the company's request. 00:00:17.455 -- 00:00:22.556 I will now turn the call over to Noel Kurdi, Vice President of Investment 00:00:22.556 -- 00:00:27.477 Relations at Apogee. Noel, you may begin. 00:00:29.090 -- 00:00:33.711 Thank you, operator, and thank you all for joining us today. 00:00:36.593 -- 00:00:41.655 During this call, we will be making forward-looking statements related to our current 00:00:41.655 -- 00:00:43.176 expectations 00:00:43.176 -- 00:00:49.299 and plans for the company, as well as our clinical and preclinical programs. 00:00:49.299 -- 00:00:54.721 These statements represent our views as of this date and should not be relied upon 00:00:54.721 -- 00:01:00.283 as representing our views as of any subsequent date in the future. 00:01:01.054 -- 00:01:06.138 Looking at our agenda today, CEO Michael Henderson will begin the call with an 00:01:06.138 -- 00:01:11.183 introduction to today's results and the opportunity in atopic 00:01:11.183 -- 00:01:12.744 dermatitis. 00:01:12.744 -- 00:01:18.008 Then, Chief Medical Officer Carl Dambkowski will walk us through the APEX 00:01:18.008 -- 00:01:23.093 Part A 52-week maintenance results of Zumilocobar 00:01:23.093 -- 00:01:28.197 in patients with moderate to severe atopic dermatitis. 00:01:28.197 -- 00:01:33.220 Dr. Ruthann Flakels of Brigham and Women's Hospital and Harvard 00:01:33.220 -- 00:01:38.964 Medical School will then share an update on the unmet ne...